CN107898815A - A kind of animal inactivation lactobacillus preparation and application thereof - Google Patents
A kind of animal inactivation lactobacillus preparation and application thereof Download PDFInfo
- Publication number
- CN107898815A CN107898815A CN201711284141.0A CN201711284141A CN107898815A CN 107898815 A CN107898815 A CN 107898815A CN 201711284141 A CN201711284141 A CN 201711284141A CN 107898815 A CN107898815 A CN 107898815A
- Authority
- CN
- China
- Prior art keywords
- inactivation
- lactobacillus
- animal
- preparation
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002779 inactivation Effects 0.000 title claims abstract description 95
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 82
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 82
- 241001465754 Metazoa Species 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 230000003115 biocidal effect Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000003921 oil Substances 0.000 claims abstract description 15
- 239000006041 probiotic Substances 0.000 claims abstract description 15
- 235000018291 probiotics Nutrition 0.000 claims abstract description 15
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 14
- 210000000214 mouth Anatomy 0.000 claims abstract description 14
- 230000001580 bacterial effect Effects 0.000 claims abstract description 13
- 230000000529 probiotic effect Effects 0.000 claims abstract description 12
- 239000000341 volatile oil Substances 0.000 claims abstract description 11
- 241001478240 Coccus Species 0.000 claims abstract description 10
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 10
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 9
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 9
- 241000238631 Hexapoda Species 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 210000003708 urethra Anatomy 0.000 claims abstract description 8
- 239000000730 antalgic agent Substances 0.000 claims abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 7
- 210000000056 organ Anatomy 0.000 claims abstract description 7
- 230000001850 reproductive effect Effects 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 63
- 241000894006 Bacteria Species 0.000 claims description 50
- 235000014655 lactic acid Nutrition 0.000 claims description 31
- 239000004310 lactic acid Substances 0.000 claims description 31
- 239000000829 suppository Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 239000005844 Thymol Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 229940070765 laurate Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- 241000194108 Bacillus licheniformis Species 0.000 claims description 2
- 244000063299 Bacillus subtilis Species 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- 241000193171 Clostridium butyricum Species 0.000 claims description 2
- 239000005770 Eugenol Substances 0.000 claims description 2
- 244000182067 Fraxinus ornus Species 0.000 claims description 2
- 235000002917 Fraxinus ornus Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 2
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 2
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 2
- 235000007746 carvacrol Nutrition 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 239000010642 eucalyptus oil Substances 0.000 claims description 2
- 229940044949 eucalyptus oil Drugs 0.000 claims description 2
- 229960002217 eugenol Drugs 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001289 litsea cubeba fruit oil Substances 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 241000606124 Bacteroides fragilis Species 0.000 claims 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims 1
- 240000004784 Cymbopogon citratus Species 0.000 claims 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims 1
- 241000254109 Tenebrio molitor Species 0.000 claims 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 1
- 229940043350 citral Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 abstract description 11
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 10
- 210000001215 vagina Anatomy 0.000 abstract description 10
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000003128 head Anatomy 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241001071864 Lethrinus laticaudis Species 0.000 description 6
- 244000057717 Streptococcus lactis Species 0.000 description 6
- 235000014897 Streptococcus lactis Nutrition 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 206010046914 Vaginal infection Diseases 0.000 description 6
- 201000008100 Vaginitis Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 4
- -1 antibiotic Substances 0.000 description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241000186869 Lactobacillus salivarius Species 0.000 description 3
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 3
- 241001502500 Trichomonadida Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 208000030373 chronic endometritis Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 229960005287 lincomycin Drugs 0.000 description 3
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000004145 Endometritis Diseases 0.000 description 2
- 241000186712 Lactobacillus animalis Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000218492 Lactobacillus crispatus Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 241001561398 Lactobacillus jensenii Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000186870 Lactobacillus ruminis Species 0.000 description 2
- 241000186783 Lactobacillus vaginalis Species 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 241000020993 Metria Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000191996 Pediococcus pentosaceus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001481656 Stratiomyidae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000004171 acute endometritis Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 235000020299 breve Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229940084434 fungoid Drugs 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 229940100618 rectal suppository Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 244000032014 Java citronella Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 206010062233 Uterine infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Include inactivation lactobacillus cell with lactobacillus preparation and application thereof, the preparation is inactivated the invention discloses a kind of animal, the inactivation lactobacillus cell includes the one or more in the bacterial strain of lactobacillus, Bifidobacterium or the Coccus inactivated；The animal further includes the one or more in prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plants essential oil, insect oils and active probiotic with inactivation lactobacillus preparation.The inactivation lactobacillus cell includes at least a kind of lactobacillus of inactivation and/or a kind of bacterial strain of the Bifidobacterium of inactivation.The inactivation lactobacillus cell is at least 108‑1011A/gram.Present invention additionally comprises be used to prevent in animal intestinal tract, dam reproductive organs (vagina and uterus), urethra, oral cavity or respiratory infection diseases medicine or sanitary health drug by above-mentioned animal inactivation lactobacillus preparation.Product of the present invention has the advantages that safe and reliable, applied widely.
Description
Technical field
The present invention relates to animal probiotics field, and in particular to and it is single made of a kind of inactivation lactic acid bacteria, or
To inactivate based on lactic acid bacteria, and composition (prebiotics, antibiotic, anodyne, medium chain fatty acid and its glycerine containing other compositions
Ester, plants essential oil, insect oils and active probiotic) preparation, it is raw for preventing animal rectum, dam (pig, cattle and sheep etc.)
Grow inflammation, pathogenic microorganism infection and the health care of organ (vagina and uterus), urethra etc..
Background technology
With the development of modern intensive aquaculture, every dam year litter size is continuously improved, while artificial insemination substitutes
Traditional mating fertilization, lack of standardization and sterilization of instruments is tight, Process of Insemination is vulnerable to microorganism infection due to operating, childbirth with
May also cause microorganism infection during midwifery, so as to cause birth canal, vulneratio uteri and infection, be susceptible to suffer from various diseases, as dam is anxious,
Chronic endometritis, retained afterbirth, vaginitis, trichomonad or candidal vaginitis, and difficult labour etc., seriously affect production effect
Rate.The above illness medicine based on chemical agent and antibiotic is currently mainly used made of suppository prevented.But these
The use of suppository can cause the microorganism species such as vagina, rectum to change, and severe patient can cause microecological balance to destroy, and beneficial bacterium is such as
Lactic acid bacteria is reduced；Meanwhile chemical agent and antibiotic etc. can cause the problems such as drug Resistance of Pathogenic Microorganism from Surface, occur weak curative effect, easily
Recurrence etc., shortcoming is obvious.It is perfect not enough and though the product such as active probiotic suppository has certain therapeutic effect, because of viable bacteria
Product is sensitive to environmental change, and transport needs whole cold chain with storage, therefore there are many use limitations.
Livestock and poultry diarrhea is also common intestines problem, and significant negative impact is caused to growth performance.Conventional control abdomen at present
The method rushed down is by adding various additives, such as antibiotic, zinc oxide, acidulant, probiotics in feed, by oral
The feed of the component containing the above and achieve the purpose that prevent diarrhea.Clinically then general the methods of using injection of antibiotics, treats abdomen
Rush down.But oral slowly effect, cultivation site injection operation can cause the stress reaction of animal.
Cultivated animals respiratory tract infection is also common disease, be easy to cause cross-infection, mixed infection and scabies secondary infection,
High risks are brought to aquaculture and cause huge economic losses.
The content of the invention
To solve the above problems, the present invention provides a kind of animal inactivation lactic acid bacteria system safe and reliable, prevention effect is good
Agent and application thereof, compared with antibiotics or live probiotic mushroom preparation, inactivation lactobacillus preparation of the invention is more stable, more may be used
Lean on, is safer, using more convenient, many restrictions of no viable bacteria class preparation.
The technical solution adopted by the present invention is：A kind of animal inactivation lactobacillus preparation, including inactivation lactobacillus cell, institute
State the one or more in the bacterial strain of lactobacillus of the inactivation lactobacillus cell including inactivation, Bifidobacterium or Coccus；Institute
State animal and further include prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plant essence with inactivation lactobacillus preparation
One or more in oil, insect oils and active probiotic.
A kind of purposes the present invention also provides animal with inactivation lactobacillus preparation, including above-mentioned animal is used into inactivation lactic acid bacteria
Preparation is used to prevent animal intestinal tract, dam (pig, ox, sheep etc.) reproductive organs (vagina and uterus), urethra, oral cavity and respiratory tract sense
Contaminate disease medicament or sanitary health drug.
The beneficial effects of the present invention are：Product of the present invention, which uses, glues animal intestinal tract, genital tract or oral cavity and respiratory tract
Film have compared with strongly adherent can inactivation lactic acid bacteria be active ingredient, available for animals' reproduction road or rectum health care, prevent it is viral,
Bacillary, fungoid genital tract, enteric infection, a variety of genital tracts and intestines problem, such as animal intestinal tract inflammation and diarrhea；Such as mother
Raise (pig, ox, sheep etc.) acute and chronic endometritis, retained afterbirth, vaginitis, trichomonad or candidal vaginitis, and difficult labour
Deng；Moreover it is possible to prevent animal urethra, oral cavity and respiratory tract infection.Compared with traditional prebiotic mushroom suppository, spray, inactivation
The unconditional pathogenicity of lactobacillus preparation, it is safer；Transport storage is more stable, more convenient without cold chain；Killed from antibiotic etc.
Bacterium, bacteriostatic agent influence, thus without withdrawal time, and use scope is wider.The preparation of the present invention program using inactivation lactic acid bacteria,
Not regrowth and breeding, thus can be used at the same time with antibiotic etc., play a role so as to cooperate with, while can effectively remain locally micro-
The ecological balance, reduction use negative effect caused by antibiotic, prevent that the microorganism species such as enteron aisle, vagina are disorderly, beneficial bacterium is such as
Lactic acid bacteria is reduced, or the generation of antibiotic-associated diarrhea.
Embodiment
For the technology contents that the present invention will be described in detail, the objects and the effects, it is explained below in conjunction with embodiment.
The design of most critical of the present invention is：Using lactobacillus cell and the prebiotics of inactivation, antibiotic, anodyne, in
One or more of collaborations in chain fatty acid and its glyceride, plants essential oil, insect oils or active probiotic are used for animal body
In enteron aisle, reproductive organs (vagina and uterus), urethra, oral cavity and respiratory infection diseases medicine, therapeutic effect is more preferable, security
Higher.
A kind of animal inactivation lactobacillus preparation, including inactivation lactobacillus cell, the inactivation lactobacillus cell include going out
One or more in the bacterial strain of lactobacillus living, Bifidobacterium or Coccus；Animal inactivation lactobacillus preparation
Further include prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plants essential oil, insect oils or active probiotic
In one or more.
As can be seen from the above description, the beneficial effects of the present invention are：Product of the present invention is used to animal intestinal tract and genitals
Official (vagina and uterus), and oral cavity and respiratory mucosa have compared with strongly adherent can lactic acid bacteria killed cells for effectively into
Point, available for animals' reproduction organ (vagina and uterus), rectum health care, diminish inflammation, prevent viral, bacillary or fungoid
The disease such as infection, a variety of genitals and intestinal inflammatory and cervical erosion, such as intestinal inflammatory and diarrhea；Such as dam (pig, ox, sheep)
Acute and chronic endometritis, retained afterbirth, vaginitis, trichomonad or bead-containing bacteria vaginitis, and difficult labour etc.；Moreover it is possible to prevent
Urethra, oral cavity and respiratory tract infection.
Preferably, the inactivation lactobacillus cell includes at least a kind of lactobacillus of inactivation or a kind of bifid of inactivation
The bacterial strain of Bacillus.
It is highly preferred that the inactivation lactobacillus cell includes at least a kind of lactobacillus of inactivation and a kind of bifid of inactivation
The composition of the bacterial strain of Bacillus.
Further, the inactivation lactobacillus cell is at least 108-1011A/gram, preferably at least contain 1010-1011
A/gram.
Preferably, the inactivation lactobacillus cell is one kind in the bacterial strain of lactobacillus, Bifidobacterium or Coccus
Or after a variety of fermentations respectively, cell, sterile water or sterile saline cleaning cell mud are centrifuged or be separated by filtration, is carried out after suspension
High-temperature inactivation；Preferably 60 DEG C -121 DEG C of inactivation temperature maintains -60 minutes 30 minutes；Ensure without lactobacillus cell living, at the same time
The form of cell is still complete, and percentage of head rice reaches 80%-90% or more；It is made after the bacteria suspension of acquisition high cell concentration or drying
Powder.
Further, the inactivation lactobacillus strains include but not limited to：Lactobacillus Jensenii (Lactobacillus
Jensenii) vagina separation strains 1153, Yue Shi lactobacillus (Lactobacillus johnsonii), Lactobacillus crispatus
(Lactobacillus crispatus), lactobacillus reuteri (Lactobacillus reuterii), Lactobacillus casei
(Lactobacillus casei), Lactobacillus salivarius (Lactobacillus salivarius), Lactobacillus animalis
(Lactobacillus animalis), Lactobacillus brevis (Lactobacillus breve), lactobacillus ruminis
(Lactobacillus ruminis), lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus gasseri
(Lactobacillus gasseri), Lactobacillus rhamnosus (Lactobacillus rhamnosus), lactobacillus plantarum
(Lactobacillus plantarum), lactobacillus fermenti (Lactobacillus fermentum), Lactobacillus delbrueckii strain breast
One or more in subspecies (Lactobacillus delbrueckii subsp.Lactis.).
Further, the Heat-killed Bifidobacterium On Microflora category bacterial strain (Bifidobacterium spp.) includes but not limited to：It is short
Bifidobacterium (Lactobacillus breve), two Bifidobacteriums (Bifidobacterium bifidum), chain bifid bar
Bacterium (Bifidobacterium catenulatum), bifidobacterium longum (Bifidobacterium longum), plant bifid bar
Bacterium (Bifidobacterium plantarum), bifidobacterium infantis (Bifidobacterium infantis), youth bifid
Bacillus (Bifidobacterium adolescentis), bifidobacterium lactis (Bifidobacterium lactis), tooth bifid
One or more in bacillus (Bifidobacterium dentium).
Further, the inactivation Coccus bacterial strain includes but not limited to：Enterococcus faecalis (Enterococcus
Faecalis), streptococcus fecalis (Streptococcus faecalis), enterococcus faecium (Enterococcus faecium), breast
Sour piece coccus (Pedioccoccusacidi lactici), thermophilus bacterial strain (Streptococcus thermophilus),
Pediococcus pentosaceus (Pediococcus pentosaceus), streptococcus lactis (Streptococcus lactis), Lactococcus lactis
One or more in (Lactococcus lactis).
Preferentially, the active probiotic also includes in the probiotics such as above-mentioned lactobacillus class, Bifidobacterium class and coccus
One or more.
Further, the active probiotic includes but not limited to：Bacillus subtilis, bacillus licheniformis, fragile plan
One or more in bacillus or clostridium butyricum.
Further, the prebiotics includes but not limited to：It is inulin, manna oligosacchride, oligofructose, galactooligosaccharide, low
One or more in xylan, fructooligosaccharide, oligoisomaltose.
Further, the plants essential oil includes but not limited to：Cinnamic acid, Thymol, eugenol, carvacrol, lemon
One or more in aldehyde, galic essential oil, litsea cubeba oil, oil of Cymbopogon winterianus and eucalyptus oil etc..
Further, the animal further includes other antifungal agents with inactivation lactobacillus preparation and other are pharmaceutically acceptable
Composition of medicine.
The antifungal agent includes but not limited to one kind or several in clotrimazole, Naftifine, nystatin, natamycin
Kind.
Further, the animal further includes antibacterial agent and other pharmaceutically acceptable group with inactivation lactobacillus preparation
Composite medicine.
The antibacterial agent includes but not limited to Ceftiofur, lincomycin, aureomycin, streptomysin and metronidazole etc..
Further, the anodyne is preferably ether etc..
Preferably, the medium chain fatty acid and its glyceride, are the laurate and Glycerol Monolaurate of 12 carbon.
Further, the medium chain fatty acid and its glyceride are included from -12 carbon fatty acid of 6 carbon and its single or multiple sweet ester,
The medium chain fatty acid includes the one or more in sour (C6), sad (C8), capric acid (C10) or laurate (C12).
Further, the animal can also include excipient with inactivation lactobacillus preparation, and the excipient includes long-chain
The glyceryl stearate of fatty glyceride, such as 18 carbon.
Further, the animal with inactivation lactobacillus preparation be suppository, tablet, capsule, soft capsule, pre-filling injection agent,
Ointment, lavage solution or mouth and nose spray.
As can be seen from the above description, the beneficial effects of the present invention are：Product of the present invention is to inactivate lactic acid bacteria as main component
The forms such as pre-filling injection agent, rectal suppository, capsule and mouth and nose spray are prepared as, with antibiotics or live probiotic mushroom preparation
To compare, invention formulation effect is more stable, more reliable, safer, using more convenient, without many restrictions of viable bacteria class preparation,
The microecological balance in animal body can be maintained at the same time.
Preferably, the animal is suppository or mouth and nose spray with inactivation lactobacillus preparation.
As can be seen from the above description, the beneficial effects of the present invention are：By mouth and nose spray offer medicine treatment respiratory tract infection or
Rectal suppository dispensing prevention diarrhea, medicine is directly launched at sufferer, take effect speed faster.
A kind of purposes the present invention also provides animal with inactivation lactobacillus preparation, including above-mentioned animal is used into inactivation lactic acid bacteria
Formulation application is in prevention animal intestinal tract, dam (pig, ox, sheep etc.) reproductive organs (vagina, uterus), urethra, oral cavity or respiratory tract
In infectious disease medicine or the medicine of health care.
Further, it is various dynamic with inactivation lactobacillus preparation to be applicable to aquatic products, herding, poultry etc. to animal of the invention
Thing.
" include but not limited to " to each mean alleged by the present invention in addition to one or more of in the object including enumerating, can be with
Including othering the material with similarity, and following newfound analog.
Embodiment 1：Animal of the present invention is as follows with the preparation method that lactic acid bacteria powder is inactivated in inactivation lactobacillus preparation：It can join
The patent ZL200810068138.X for examining this research department is implemented, specific as follows：Lactobacillus, the bifid in above-mentioned lactic acid bacteria are taken respectively
Bacillus or coccus pure culture, activation and picking single bacterium colony in solid-state MRS cultures；Picking single bacterium colony accesses MRS or changes
Good liquid MRS culture mediums, when 30 DEG C of -37 DEG C of culture 12-18 are small, cell at this time is in exponential phase, and cell number reaches
108-109CFU/ml.Above-mentioned ready seed is accessed in liquid fermentation base in 3%-5% (v/v) ratio, it is static or slow
Stirring, when 30 DEG C of -37 DEG C of culture 18-24 are small, cell number is up to 10 at this time8-109CFU/ml；Stop fermentation, side is stirred and risen
Height fermentation base temperature maintains 30 minutes, to ensure cell inactivation, but lactobacillus cell is still complete, and percentage of head rice reaches to 80 DEG C
90%；Centrifugation, collects the lactobacillus cell of inactivation；Sterile water or sterile saline cleaning are added, removes remaining fermentation base
With solable matter；Take appropriate excipient, such as glucose, oligofructose, or starch etc., in proportion with the killed cells of collection
Wet bacterium mud mixing；Vacuum drying or vacuum freeze drying；Low-temperature grinding, the sieving of 80-100 mesh；Obtain going out for single lactic acid bacteria
Living cells high concentrate clust, cell content are 1 × 1010-2×1010A/gram.Load sterile vacuum bag, sealing preservation, is sticked
Label, it is spare.
Embodiment 2：A kind of preparation of the animal inactivation compound suppository of lactic acid bacteria：Inactivation lactic acid bacteria prepared by Example 1
15 parts of powder, wherein take 7.5 parts of the lactobacillus acidophilus of inactivation respectively, 7.5 parts of bifidobacterium infantis, both killed cells numbers are
2×1010A/gram；5 parts of oligofructose, 80 parts of tristerin；Lactic acid bacteria will be inactivated, oligofructose adds the tristearin of fusing
In acid glyceride, vaginal plug mould is fed into after stirring evenly, cools down, scabble, Qi Mo, packing animal up to suppository form with going out
Live acid bacteria preparation.Every or about 1 gram -10 grams of per unit suppository, according to using depending on animal body size.
Embodiment 3 inactivates the purposes of lactobacillus preparation for a kind of animal：By the animal of the embodiment 2 sour bacteria preparation of inactivation
For preventing the infection of sow birth canal, prevent hysteritis or endometritis.
Select natural labor, grown in vain without breeding difficulty through producing standby pregnant sow 60, every group 30, be divided into experimental group and control group.
Experimental group is in breeding the last week, and with special pusher by the suppository in 1 embodiment 1,5g containing effective ingredient, is pushed into uterus or the moon
Road；Control group does not process, other rearing conditions and management operation are consistent.
Testing result finds that between test group sow vaginal mucus pH maintains 6.0-6.8, and control group pH is 7.2-
Between 8.0, significant difference (P<0.05)；Test group Lactobacillus vaginalis number about 1 × 107-108CFU/ml, control group about 1 ×
106-107CFU/ml, the Lactobacillus vaginalis number of test group substantially increase (P<0.05).And by long-term it has been observed that repeatedly
The experimental group sow postpartum reproductive tract infection of inactivation lactic acid bacteria of the invention and the number of inflammation has been used to reduce 90% than control group,
Significant difference (P<0.05).And Recovery situation, the health status of piglet of experimental group are better than control group.Therefore, originally
Invention product has good preventive effect.
Embodiment 4 inactivates lactic acid bacteria complex capsule preparation for a kind of animal：Inactivation lactic acid bacteria powder prepared by Example 1
50 parts (wherein 20 parts of Lactobacillus salivarius, 20 parts of bifidobacterium adolescentis, 10 parts of lactic acid chain bacterium balls), the killed cells number of three's original powder
It is 2 × 1010A/gram；5 parts of iodoform, 5 parts of the active polypeptide lactobacillus powder of coating, 5 parts of Glycerol Monolaurate, magnesium stearate 5
Part, 30 parts of lactose；Mentioned component is quantified into mixing, after stirring evenly, it is 1 × 10 to inactivate lactobacillus cell in pulvis at this time10A/
G, pours into capsule.
Embodiment 5：The animal of the embodiment 4 sour bacterium capsule preparations of inactivation are applied to treatment sow reproductive tract infection.Choosing
The sow 50 with reproductive tract infection is selected, is divided into experimental group and control group, every group 25.Experimental group is used in embodiment 4
Capsule, twice daily, one piece every time, 5 days as one therapeutic course, the therapeutic effect after a course for the treatment of is as shown in table 1 below, and table 1 is the present invention
The treatment results statistical form of embodiment 5.
The treatment results statistical form of 1 embodiment of the present invention 5 of table
| Group | Head number | Cure head number | Improve head number | Invalid head number | It is efficient |
| Experimental group | 25 | 18 | 5 | 2 | 92% |
| Control group | 25 | 0 | 2 | 23 | 8.0% |
As it can be seen from table 1 being treated using medicine of the present invention, therapeutic effect is up to 92%, it can be achieved that good controls
Therapeutic effect, observe experimental group can effectively treat the reproductive tract infection of sow.
Embodiment 6：A kind of animal inactivation lactobacillus preparation：15 parts of inactivation lactic acid bacteria prepared by Example 1, wherein dividing
7.5 parts of the lactobacillus acidophilus of inactivation is not taken, and 7.5 parts of bifidobacterium infantis, both killed cells numbers are 2 × 1010A/gram；
1 part of lincomycin, 1 part of clotrimazole, 3 parts of oligofructose, 80 parts of tristerin；Will inactivation lactic acid bacteria, lincomycin, gram mould
Azoles, oligofructose are added in the tristerin of fusing, are fed into after stirring evenly in vaginal plug mould, are cooled down, scabble, open
Mould, the animal inactivation lactobacillus preparation for packing suppository form to obtain the final product.Every or about 1 gram -10 grams of per unit suppository, according to use
Depending on animal body size.
Embodiment 7：A kind of animal is with the inactivation compound suppository formulations of lactic acid bacteria in milk cow metria prophylactic applications：Selection
Firm natural labor through milking cow 60, be divided into experimental group and control group, every group 30, experimental group will be real after afterbirth comes off in postpartum
The suppository described in example 6 is applied, 5g containing active ingredient is pushed into cow uteri, daily one, is used within continuous three days, control group does not make
With remaining Routine Management is identical.Observe experimental group postpartum uterine infection declines to a great extent than control group, decline up to 83.3%, it is poor
Different significantly (P<0.05), and postpartum experimental group recovery situation is better than control group.Therefore, the present invention is to the pre- of milk cow metria
It is anti-to work well.
Embodiment 8：A kind of animal, which is used, inactivates lactobacillus preparation, 30 parts of inactivation lactic acid bacteria powder in Example 1, wherein knurl
15 parts of stomach lactobacillus, 15 parts of enterococcus faecium, both killed cells numbers are 2 × 1010A/gram；45 parts of plants essential oil, wherein meat
20 parts of cinnamic aldehyde, 20 parts of Thymol, 5 parts of galic essential oil, 10 parts of oligofructose, 2 parts of iodoform, 3 parts of ether, 10 parts of magnesium stearate,
Pour into capsule, every capsule is 5 grams.
Embodiment 9：A kind of application of animal with inactivation lactobacillus preparation in milk cow lochia discharges serious nursing：Choosing
Select lochia and discharge serious milk cow 50, be divided into experimental group and control group, experimental group takes the glue of gained in two embodiments 8
Capsule, which is cut off, to be dissolved in the warm water of 200ml 35-40 DEG C, and preparation is sent into uterus with ox with vas deferens, once a day, continues three days,
Control group does not process, other management operations are consistent.Observe, experimental group lochia discharge situation is obviously improved after three days, is compared
Improve according to a group lochia discharge situation up to more than 90%, positive effect, and it is excellent to test the overall recovery situation of milk cow, feed intake etc.
In control group.
Embodiment 10：A kind of animal inactivation lactobacillus preparation：15 parts of inactivation lactic acid bacteria part in Example 1, wherein
7.5 parts of lactobacillus acidophilus, 7.5 parts of Lactobacillus rhamnosus, killed cells number is 2 × 1010A/gram, black soldier flies insect oils 25
Part, 3 parts of Lactococcus lactis living, 57 parts of tristerin.Will inactivation lactic acid bacteria and Lactococcus lactis and black soldier flies insect oils
After mixing, add in the tristerin of dissolving, be fed into after stirring evenly in vaginal plug mould, cool down, scabble, Qi Mo, bag
The animal inactivation lactobacillus preparation up to suppository form is filled, active ingredient is 2g every.
Embodiment 11：A kind of application of animal with inactivation lactobacillus preparation in diarrhea piggy prevents：Selective body heavy phase is near,
90 of about 25kg suffer from the piggy of mild diarrhea, and after diagnosing, which meets bacillary and virus diarrhea symptom.Will
Piggy is divided into preparation group, antibiotic group, control group, every group 30.Gained in the daily rectally embodiment 10 of preparation group
Suppository 2, once a day, 5 days as one therapeutic course；Antibiotic group is handled according to conventional antibiotic treatment, and control group does not process, its
It is consistent that he manages operation.It is as shown in table 2 to take the record of the inspection result after a course for the treatment of, table 2 is the treatment of the embodiment of the present invention 11
As a result statistical form.
The treatment results statistical form of 2 embodiment of the present invention 11 of table
| Group | Originate head number | Cure head number | Improve head number | Invalid head number | Efficient (%) |
| Antibiotic group | 30 | 19 | 8 | 3 | 90 |
| Preparation group | 30 | 17 | 9 | 4 | 86 |
| Control group | 30 | 5 | 8 | 17 | 43 |
From Table 2, it can be seen that the bacterium and virus diarrhea of inactivation lactic acid bacteria and insect oils compound formulation to piggy
There is good prevention effect.
Embodiment 12：A kind of animal, which is used, inactivates lactobacillus preparation, 45 parts of inactivation lactic acid bacteria in Example 1, wherein saliva
15 parts of liquid lactobacillus, 15 parts of lactobacillus plantarum, 15 parts of bifidobacterium longum, 10 parts of oligofructose, aureomycin 5 parts (25mg/kg) are sliding
40 parts of mountain flour, uniformly spray is made in rear 80-100 mesh sieving to mixed grinding.
Embodiment 13：A kind of application of animal with inactivation lactobacillus preparation in respiratory tract infection piggy is treated：Selective body
Again etc. similar in each side condition, the piggy 60 of respiratory tract infection of pigs symptom is had, is divided into experimental group and control group, every group
30, obtained spray in experimental group daily administration embodiment 12, twice daily, 7 days as one therapeutic course, control group does not process,
Other management operations are consistent.It turns out that experimental group respiratory tract infection symptom is almost recovered, up to 86%, control group then improves not
Greatly, the obvious (p of difference<0.05).The above results illustrate that respiratory tract infection of the said preparation to pig also has good effect.
" part " in the present invention each means parts by weight.
In conclusion the present invention provides a kind of animal inactivation lactobacillus preparation and application thereof, using the present invention program system
Standby animal can be widely used for multi-infection disease with inactivation lactobacillus preparation, and the therapeutic effect of product of the present invention is good, controls
More rate is high.
The foregoing is merely the embodiment of the present invention, is not intended to limit the scope of the invention, every to utilize this hair
The equivalents that bright description is made, are directly or indirectly used in relevant technical field, are similarly included in this hair
In bright scope of patent protection.
Claims (10)
- A kind of 1. animal inactivation lactobacillus preparation, it is characterised in that：Including inactivating lactobacillus cell, the inactivation lactic acid bacteria is thin Born of the same parents include the one or more in the bacterial strain of lactobacillus, Bifidobacterium or the Coccus inactivated；Animal inactivation breast Sour bacteria preparation further include prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plants essential oil, insect oils and One or more in active probiotic.
- 2. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The inactivation lactobacillus cell is extremely A kind of lactobacillus including inactivation and/or a kind of bacterial strain of the Bifidobacterium of inactivation less.
- 3. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：It is described inactivation lactobacillus cell be After one or more fermentations in the bacterial strain of lactobacillus, Bifidobacterium or Coccus, made of after being inactivated and being dried Powder.
- 4. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The active probiotic include but The one kind or several being not limited in biodiasmin, bacillus subtilis, bacillus licheniformis, bacteroides fragilis or clostridium butyricum Kind.
- 5. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The prebiotics includes but unlimited One kind or more in inulin, manna oligosacchride, oligofructose, galactooligosaccharide, xylo-oligosaccharide, fructooligosaccharide, oligoisomaltose Kind.
- 6. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The animal uses inactivation lactic acid bacteria Preparation further includes antifungal agent or antibacterial agent and other pharmaceutically acceptable combinations.
- 7. according to the animal inactivation lactobacillus preparation described in claim 1, it is characterised in that：The medium chain fatty acid and its Glyceride includes but not limited to the one or more in caproic acid, octanoic acid, capric acid, laurate.
- 8. according to the animal inactivation lactobacillus preparation described in claim 1, it is characterised in that：The plants essential oil include but It is not limited to cinnamic acid, Thymol, eugenol, carvacrol, citral, galic essential oil, litsea cubeba oil, eucalyptus oil, lemongrass essence One or more in oil；The insect oils include but not limited to the one or more in Heisui River gadfly oil, yellow meal worm worm oil.
- 9. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The animal uses inactivation lactic acid bacteria Preparation is suppository, tablet, mouth and nose spray, capsule, soft capsule, pre-filling injection agent, ointment or lavage solution.
- It is 10. a kind of such as claim 1-9 any one of them animal purposes of inactivation lactobacillus preparation, it is characterised in that：Bag Include and be used to prevent animal intestinal tract, dam reproductive organs, urethra, oral cavity, respiratory tract sense by above-mentioned animal inactivation lactobacillus preparation Contaminate in disease medicament or sanitary health drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711284141.0A CN107898815A (en) | 2017-12-07 | 2017-12-07 | A kind of animal inactivation lactobacillus preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711284141.0A CN107898815A (en) | 2017-12-07 | 2017-12-07 | A kind of animal inactivation lactobacillus preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107898815A true CN107898815A (en) | 2018-04-13 |
Family
ID=61864915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711284141.0A Pending CN107898815A (en) | 2017-12-07 | 2017-12-07 | A kind of animal inactivation lactobacillus preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107898815A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109837229A (en) * | 2019-04-11 | 2019-06-04 | 河北维尔利动物药业集团有限公司 | The preparation method of clostridium butyricum composite bacteria liquid for poultry |
| CN111184140A (en) * | 2020-01-17 | 2020-05-22 | 金华市农业科学研究院 | A kind of feed additive for improving the production performance of egg quail |
| CN112574919A (en) * | 2020-12-18 | 2021-03-30 | 广州市微生物研究所有限公司 | Mycosporin secretion type probiotic agent as well as preparation method and application thereof |
| CN113645959A (en) * | 2018-12-19 | 2021-11-12 | 健康牛公司 | Ready-to-use probiotic composition and application thereof |
| CN115554320A (en) * | 2022-10-28 | 2023-01-03 | 江南大学 | Lactobacillus fermentum inactivated thallus capable of relieving periodontitis and application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
| CN1568365A (en) * | 2001-10-12 | 2005-01-19 | 雷丁大学 | Composition comprising a lactobacillus pentosus strain and uses thereof |
| CN101069700A (en) * | 2007-05-24 | 2007-11-14 | 郭兴华 | Composition for preventing manmmal vagina infection and use |
| CN101612169A (en) * | 2008-06-27 | 2009-12-30 | 生物源生物技术（深圳）有限公司 | Lactobacillus micro-ecological preparation of deactivation and preparation method thereof |
| CN101827600A (en) * | 2007-08-17 | 2010-09-08 | 雀巢产品技术援助有限公司 | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| CN102835657A (en) * | 2011-06-20 | 2012-12-26 | 丰华生物科技股份有限公司 | Lactic acid bacteria-containing food composition and pharmaceutical composition for inhibiting inflammatory response and anti-vaginitis |
| JP2016214107A (en) * | 2015-05-15 | 2016-12-22 | フロイント産業株式会社 | Production method of powder composition containing dead cell of lactic acid bacterium and/or bifidobacterium |
| WO2017014929A1 (en) * | 2015-07-23 | 2017-01-26 | The Procter & Gamble Company | Patch containing microorganism |
| CN106720938A (en) * | 2016-11-10 | 2017-05-31 | 四川理工学院 | A kind of compound symphysis unit probiotics and preparation method thereof |
| CN107198675A (en) * | 2017-04-20 | 2017-09-26 | 广东丸美生物技术股份有限公司 | A kind of double-deck Essence with maintenance and senile-resistant efficacy and preparation method and application |
-
2017
- 2017-12-07 CN CN201711284141.0A patent/CN107898815A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
| CN1568365A (en) * | 2001-10-12 | 2005-01-19 | 雷丁大学 | Composition comprising a lactobacillus pentosus strain and uses thereof |
| CN101069700A (en) * | 2007-05-24 | 2007-11-14 | 郭兴华 | Composition for preventing manmmal vagina infection and use |
| CN101827600A (en) * | 2007-08-17 | 2010-09-08 | 雀巢产品技术援助有限公司 | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| CN101612169A (en) * | 2008-06-27 | 2009-12-30 | 生物源生物技术（深圳）有限公司 | Lactobacillus micro-ecological preparation of deactivation and preparation method thereof |
| CN102835657A (en) * | 2011-06-20 | 2012-12-26 | 丰华生物科技股份有限公司 | Lactic acid bacteria-containing food composition and pharmaceutical composition for inhibiting inflammatory response and anti-vaginitis |
| JP2016214107A (en) * | 2015-05-15 | 2016-12-22 | フロイント産業株式会社 | Production method of powder composition containing dead cell of lactic acid bacterium and/or bifidobacterium |
| WO2017014929A1 (en) * | 2015-07-23 | 2017-01-26 | The Procter & Gamble Company | Patch containing microorganism |
| CN106720938A (en) * | 2016-11-10 | 2017-05-31 | 四川理工学院 | A kind of compound symphysis unit probiotics and preparation method thereof |
| CN107198675A (en) * | 2017-04-20 | 2017-09-26 | 广东丸美生物技术股份有限公司 | A kind of double-deck Essence with maintenance and senile-resistant efficacy and preparation method and application |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113645959A (en) * | 2018-12-19 | 2021-11-12 | 健康牛公司 | Ready-to-use probiotic composition and application thereof |
| CN109837229A (en) * | 2019-04-11 | 2019-06-04 | 河北维尔利动物药业集团有限公司 | The preparation method of clostridium butyricum composite bacteria liquid for poultry |
| CN111184140A (en) * | 2020-01-17 | 2020-05-22 | 金华市农业科学研究院 | A kind of feed additive for improving the production performance of egg quail |
| CN112574919A (en) * | 2020-12-18 | 2021-03-30 | 广州市微生物研究所有限公司 | Mycosporin secretion type probiotic agent as well as preparation method and application thereof |
| CN115554320A (en) * | 2022-10-28 | 2023-01-03 | 江南大学 | Lactobacillus fermentum inactivated thallus capable of relieving periodontitis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107898815A (en) | A kind of animal inactivation lactobacillus preparation and application thereof | |
| US20200069749A1 (en) | Lactobacillus-based ecoli inhibition | |
| WO2022100633A1 (en) | Lactobacillus gasseri for prevention and/or treatment of reproductive tract flora disorder-related diseases | |
| CN107815432B (en) | Inactivated lactobacillus preparation for human and application thereof | |
| RU2316586C2 (en) | PROBIOTIC STRAINS OF Lactobacillus (VARIANTS) AND THEIR USING | |
| FI122247B (en) | Probiotic preparation for the prevention or treatment of dogs gastrointestinal disorders | |
| US8222020B2 (en) | Biologically pure strain of Lactobacillus fermentum, strain Ess-1 | |
| AU2016353091B2 (en) | Probiotic delivery systems | |
| US20240066078A1 (en) | Strains, compositions and methods of use | |
| MX2012011270A (en) | Animal feed for calves for conditioning the intestinal flora. | |
| CN117143783B (en) | Saliva combined lactobacillus VB330 and application thereof | |
| CN104450590A (en) | Bacillus subtilis with antibacterial activity and application of bacillus subtilis | |
| CN108753650A (en) | Enterococcus faecium and compound micro-ecological preparation prepared therefrom | |
| CN109402002A (en) | Lactobacillus gasseri and application thereof in preparation of premature delivery prevention medicine | |
| WO2003039260A2 (en) | Probiotic compositions | |
| AU2002348340A1 (en) | Probiotic compositions | |
| CN107714672B (en) | A kind of woman's vagina active probiotic gel packing and preparation method thereof | |
| CN103333830B (en) | Pig source enterococcus faecalis, microbial ecological agent and application thereof | |
| JP4243622B2 (en) | Livestock breeding method | |
| Boaventura et al. | The benefits of probiotics in human and animal nutrition | |
| RU2119796C1 (en) | Complex probiotic preparation for animals | |
| CN113186118B (en) | A compound probiotic preparation for improving the production performance of sows and its preparation method | |
| KR100993562B1 (en) | Lactobacillus strains | |
| CN116801893A (en) | Strains, compositions and methods of use | |
| Pedersen et al. | Transfer of lactic acid bacterial strains from the feed to the sow, the environment, and the piglets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180413 |